Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease
Open accessAbstract
Background & aims The histopathology of nonalcoholic fatty liver disease (NAFLD) is similar to that of alcoholic liver disease. Colonic bacteria are a source of many metabolic products, including ethanol and other volatile organic compounds (VOC) that may have toxic effects on the human host after intestinal absorption and delivery to the liver via the portal vein. Recent data suggest that the composition of the gut microbiota in obese human beings is different from that of healthy-weight individuals. The aim of this study was to compare the colonic microbiome and VOC metabolome of obese NAFLD patients (n = 30) with healthy controls (n = 30). Methods Multitag pyrosequencing was used to characterize the fecal microbiota. Fecal VOC profiles were measured by gas chromatography-mass spectrometry. Results There were statistically significant differences in liver biochemistry and metabolic parameters in NAFLD. Deep sequencing of the fecal microbiome revealed over-representation of Lactobacillus species and selected members of phylum Firmicutes (Lachnospiraceae; genera, Dorea, Robinsoniella, and Roseburia) in NAFLD patients, which was statistically significant. One member of phylum Firmicutes was under-represented significantly in the fecal microbiome of NAFLD patients (Ruminococcaceae; genus, Oscillibacter). Fecal VOC profiles of the 2 patient groups were different, with a significant increase in fecal ester compounds observed in NAFLD patients. Conclusions A significant increase in fecal ester VOC is associated with compositional shifts in the microbiome of obese NAFLD patients. These novel bacterial metabolomic and metagenomic factors are implicated in the etiology and complications of obesity.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Dysbiosis of the gut microbiota has been observed in obese patients with MAFLD, with increasing Lactobacillus, Dorea, Robinsoniella and Roseburia.
“Dysbiosis of the gut microbiota has been observed in obese patients with MAFLD, with increasing Lactobacillus, Dorea, Robinsoniella and Roseburia (Raman et al., 2013).”
From <i>Akkermansia muciniphila</i> alleviates <scp>high‐fat‐diet</scp> ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Raman et al., 2013
Cites
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · see citing works
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227 · see citing works
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302 · see citing works
“A lower proportion of Ruminococcaceae was noted in patients with NASH compared with healthy subjects 42 and a study which characterised gut microbiota of children with NASH, obesity and healthy controls showed that patients with NASH had a higher proportion of Escherichia compared with other groups.”
ResultMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002 · see citing works
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480 · see citing works
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020 · see citing works
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971 · see citing works
Diet and feeding pattern affect the diurnal dynamics of the gut microbiome
Zarrinpar, A., Chaix, A., Yooseph, S., & Panda, S. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.11.008 · Cited by 926 · see citing works
Therapeutic Potential of Fecal Microbiota Transplantation
Smits, L. P., Bouter, K. E. C., de Vos, W. M., Borody, T. J., & Nieuwdorp, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.058 · Cited by 717 · see citing works
Del Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696 · see citing works
Effects of antibiotics on gut microbiota
Lange, K., Buerger, M., Stallmach, A., & Bruns, T. (2016) · Digestive Diseases · doi:10.1159/000443360 · Cited by 607 · see citing works
Gut microbiome and liver diseases
Tilg, H., Cani, P. D., & Mayer, E. A. (2016) · Gut · doi:10.1136/gutjnl-2016-312729 · Cited by 525 · see citing works
Zhou, D., Pan, Q., Xin, F.-Z., Zhang, R.-N., He, C.-X., Chen, G.-Y., Liu, C., Chen, Y.-W., & Fan, J.-G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.60 · Cited by 441 · see citing works
Puri, P., Daita, K., Joyce, A., Mirshahi, F., Santhekadur, P. K., Cazanave, S., Luketic, V. A., Siddiqui, M. S., Boyett, S., Min, H., et al. (2018) · Hepatology · doi:10.1002/hep.29359 · Cited by 426 · see citing works
Gut Microbiota Profiling: Metabolomics Based Approach to Unravel Compounds Affecting Human Health
Vernocchi, P., Del Chierico, F., & Putignani, L. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01144 · Cited by 426 · see citing works
Role of the gut microbiota in type 2 diabetes and related diseases
Yang, G., Wei, J., Liu, P., Zhang, Q., Tian, Y., Hou, G., Meng, L., Xin, Y., & Jiang, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154712 · Cited by 418 · see citing works
RETRACTED ARTICLE: Role of the gut microbiome in chronic diseases: a narrative review
Vijay, A., & Valdes, A. M. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00991-6 · Cited by 361 · see citing works
RetractedChu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354 · see citing works
Da Silva, H. E., Teterina, A., Comelli, E. M., Taibi, A., Arendt, B. M., Fischer, S. E., Lou, W., & Allard, J. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-19753-9 · Cited by 283 · see citing works
Non-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241 · see citing works
Scorletti, E., Afolabi, P. R., Miles, E. A., Smith, D. E., Almehmadi, A., Alshathry, A., Childs, C. E., Del Fabbro, S., Bilson, J., Moyses, H. E., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.031 · Cited by 237 · see citing works
The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease
Parekh, P. J., Balart, L. A., & Johnson, D. A. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.16 · Cited by 219 · see citing works
The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse
Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115225 · Cited by 197 · see citing works
A mountable toilet system for personalized health monitoring via the analysis of excreta
Park, S.-M., Won, D. D., Lee, B. J., Escobedo, D., Esteva, A., Aalipour, A., Ge, T. J., Kim, J. H., Suh, S., Choi, E. H., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0534-9 · Cited by 175 · see citing works
Chiu, C.-C., Ching, Y.-H., Li, Y.-P., Liu, J.-Y., Huang, Y.-T., Huang, Y.-W., Yang, S.-S., Huang, W.-C., & Chuang, H.-L. (2017) · Nutrients · doi:10.3390/nu9111220 · Cited by 160 · see citing works
Lagoumintzis, G., & Patrinos, G. P. (2023) · Human Genomics · doi:10.1186/s40246-023-00561-w · Cited by 132 · see citing works
Wu, W., Kaicen, W., Bian, X., Yang, L., Ding, S., Li, Y., Li, S., Zhuge, A., & Li, L. (2023) · Microbial Biotechnology · doi:10.1111/1751-7915.14293 · Cited by 129 · see citing works
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
Loomba, R., Ling, L., Dinh, D. M., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Sanyal, A. J. (2021) · Hepatology · doi:10.1002/hep.31523 · Cited by 88 · see citing works
Melnik, A. V., da Silva, R. R., Hyde, E. R., Aksenov, A. A., Vargas, F., Bouslimani, A., Protsyuk, I., Jarmusch, A. K., Tripathi, A., Alexandrov, T., et al. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b01381 · Cited by 87 · see citing works
Gut microbiota, fatty liver disease, and hepatocellular carcinoma
Chu, H., Williams, B., & Schnabl, B. (2018) · Liver Research · doi:10.1016/j.livres.2017.11.005 · Cited by 84 · see citing works
Pataky, Z., Genton, L., Spahr, L., Lazarevic, V., Terraz, S., Gaïa, N., Rubbia-Brandt, L., Golay, A., Schrenzel, J., & Pichard, C. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4179-1 · Cited by 75 · see citing works
The Human Gut Microbiome in Liver Diseases
Davis, B., & Bajaj, J. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1602763 · Cited by 34 · see citing works
The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease
Puri, P., & Sanyal, A. J. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.009 · Cited by 33 · see citing works
- Authors
- Raman, M., Ahmed, I., Gillevet, P. M., Probert, C. S., Ratcliffe, N. M., Smith, S., Greenwood, R., Sikaroodi, M., Lam, V., Crotty, P., Bailey, J., Myers, R. P., & Rioux, K. P.
- Affiliations
- University of Calgary (CA)
- Bristol Royal Infirmary (GB)
- George Mason University (US)
- University of the West of England (GB)
- Corresponding author
- Raman, Maitreyi
- ORCID
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 11
- Issue
- 7
- Pages
- 868-875.e3
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2140571939
- Cited by
- 672
- References
- 3
- Citations by year
- 2026: 22 · 2025: 29 · 2024: 45 · 2023: 67 · 2022: 70 · 2021: 83 · 2020: 66 · 2019: 58 · 2018: 65 · 2017: 45 · 2016: 48 · 2015: 34 · 2014: 29 · 2013: 9 · 2012: 1
- FWCI
- 17.93
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.uwe.ac.uk
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- UWE Research Repository (UWE Bristol) (submittedVersion, cc-by)
- Funders
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- non-alcoholic fatty liver disease, obesity, fecal microbiota, volatile organic compounds, gut microbiota, Lactobacillus, Firmicutes, Lachnospiraceae, Oscillibacter, bacterial metabolites, alcohol metabolism, liver biochemistry
- MeSH terms
- Adult, Fatty Liver, Feces, Female, Humans, Male, Gas Chromatography-Mass Spectrometry, Middle Aged, Obesity, Case-Control Studies, Sequence Analysis, DNA, Metabolome, Volatile Organic Compounds, Biota, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
